drugset / Trial / NCT02656069

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

NCT02656069

Phase 3 Completed 80 enrolled Xeris Pharmaceuticals
RandomizedCrossoverTriple-blindTreatment

Summary

This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection \[rDNA origin\]) for hypoglycemia rescue of adult patients with type 1 diabetes.

Timeline

Start
2017-03-15
Primary completion
2017-08-14
Completion
2017-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucagon Peptide 1 mg Subcutaneous